SEARCH

SEARCH BY CITATION

LITERATURE CITED

  • 1
    Parker CJ. Historical aspects of paroxysmal nocturnal haemoglobinuria: ‘Defining the disease’. Br J Haematol 2002; 117: 322.
  • 2
    Parker CJ. Bone marrow failure syndromes: Paroxysmal nocturnal hemoglobinuria. Hematol Oncol Clin North Am 2009; 23: 333346.
  • 3
    de Latour RP, Mary JY, Salanoubat C, Terriou L, Etienne G, Mohty M, Roth S, de GS, Maury S, Cahn JY, Socie G. Paroxysmal nocturnal hemoglobinuria: Natural history of disease subcategories. Blood 2008; 112: 30993106.
  • 4
    Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995; 333: 12531258.
  • 5
    Socie G, Mary JY, de GA, Rio B, Leporrier M, Rose C, Heudier P, Rochant H, Cahn JY, Gluckman E. Paroxysmal nocturnal haemoglobinuria: Long-term follow-up and prognostic factors. French Society of Haematology. Lancet 1996; 348: 573577.
  • 6
    Bessler M, Mason PJ, Hillmen P, Luzzatto L. Mutations in the PIG-A gene causing partial deficiency of GPI-linked surface proteins (PNH II) in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 1994; 87: 863866.
  • 7
    Bessler M, Mason PJ, Hillmen P, Miyata T, Yamada N, Takeda J, Luzzatto L, Kinoshita T. Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene. EMBO J 1994; 13: 110117.
  • 8
    Takeda J, Miyata T, Kawagoe K, Iida Y, Endo Y, Fujita T, Takahashi M, Kitani T, Kinoshita T. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993; 73: 703711.
  • 9
    Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007; 25: 12561264.
  • 10
    Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, Gaya A, Coyle L, de CC, Fu CL, Maciejewski JP, Bessler M, Kroon HA, Rother RP, Hillmen P. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008; 111: 18401847.
  • 11
    Hillmen P, Hall C, Marsh JC, Elebute M, Bombara MP, Petro BE, Cullen MJ, Richards SJ, Rollins SA, Mojcik CF, Rother RP. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004; 350: 552559.
  • 12
    Hillmen P, Muus P, Duhrsen U, Risitano AM, Schubert J, Luzzatto L, Schrezenmeier H, Szer J, Brodsky RA, Hill A, Socie G, Bessler M, Rollins SA, Bell L, Rother RP, Young NS. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007; 110: 41234128.
  • 13
    Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, Roth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355: 12331243.
  • 14
    Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R, Hillmen P, Luzzatto L, Young N, Kinoshita T, Rosse W, Socie G. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005; 106: 36993709.
  • 15
    Ham TH. Hemoglobinuria. Am J Med 1955; 18: 9901006.
  • 16
    Hartmann RC, Jenkins DE. The “sugar-water” test for paroxysmal nocturnal hemoglobinuria. N Engl J Med 1966; 275: 155157.
  • 17
    Rosse WF. Dr Ham's test revisited. Blood 1991; 78: 547550.
  • 18
    HAM TH. Chronic hemolytic anemia with paroxysmal nocturnal hemoglobinuria. A study of the mechanism in relation to acid-base equilibrium. N Engl J Med 1937; 217: 915922.
  • 19
    Rosse WF, Dacie JV. Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. I The sensitivity of PNH red cells to lysis by complement and specific antibody. J Clin Invest 1966; 45: 736748.
  • 20
    Rosse WF, Hoffman S, Campbell M, Borowitz M, Moore JO, Parker CJ. The erythrocytes in paroxysmal nocturnal haemoglobinuria of intermediate sensitivity to complement lysis. Br J Haematol 1991; 79: 99107.
  • 21
    Rosse WF. Variations in the red cells in paroxysmal nocturnal haemoglobinuria. Br J Haematol 1973; 24: 327342.
  • 22
    Hall SE, Rosse WF. The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria. Blood 1996; 87: 53325340.
  • 23
    Richards SJ, Rawstron AC, Hillmen P. Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria. Cytometry 2000; 42: 223233.
  • 24
    Richards SJ, Whitby L, Cullen MJ, Dickinson AJ, Granger V, Reilly JT, Hillmen P, Barnett D. Development and evaluation of a stabilized whole-blood preparation as a process control material for screening of paroxysmal nocturnal hemoglobinuria by flow cytometry. Cytometry B 2008; 76B: 4755.
  • 25
    Hernandez-Campo PM, Almeida J, Sanchez ML, Malvezzi M, Orfao A. Normal patterns of expression of glycosylphosphatidylinositol-anchored proteins on different subsets of peripheral blood cells: A frame of reference for the diagnosis of paroxysmal nocturnal hemoglobinuria. Cytometry B 2006; 70B: 7181.
  • 26
    Wang SA, Pozdnyakova O, Jorgensen JL, Medeiros LJ, Stachurski D, Anderson M, Raza A, Woda BA. Detection of paroxysmal nocturnal hemoglobinuria clones in patients with myelodysplastic syndromes and related bone marrow diseases, with emphasis on diagnostic pitfalls and caveats. Haematologica 2009; 94: 2937.
  • 27
    Brodsky RA, Mukhina GL, Li S, Nelson KL, Chiurazzi PL, Buckley JT, Borowitz MJ. Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using fluorescent aerolysin. Am J Clin Pathol 2000; 114: 459466.
  • 28
    Hernandez-Campo PM, Almeida J, Matarraz S, de SM, Sanchez ML, Orfao A Quantitative analysis of the expression of glycosylphosphatidylinositol-anchored proteins during the maturation of different hematopoietic cell compartments of normal bone marrow. Cytometry B 2007; 72B: 3442.
  • 29
    Sutherland DR, Kuek N, Davidson J, Barth D, Chang H, Yeo E, Bamford S, Chin-Yee I, Keeney M Diagnosing PNH with FLAER and multiparameter flow cytometry. Cytometry B 2007; 72B: 167177.
  • 30
    Alfinito F, Del VL, Rocco S, Boccuni P, Musto P, Rotoli B. Blood cell flow cytometry in paroxysmal nocturnal hemoglobinuria: A tool for measuring the extent of the PNH clone. Leukemia 1996; 10: 13261330.
  • 31
    Kwong YL, Lee CP, Chan TK, Chan LC. Flow cytometric measurement of glycosylphosphatidyl-inositol-linked surface proteins on blood cells of patients with paroxysmal nocturnal hemoglobinuria. Am J Clin Pathol 1994; 102: 3035.
  • 32
    van der Schoot CE, Huizinga TW, van't Veer-Korthof ET, Wijmans R, Pinkster J, von dem Borne AE. Deficiency of glycosyl-phosphatidylinositol-linked membrane glycoproteins of leukocytes in paroxysmal nocturnal hemoglobinuria, description of a new diagnostic cytofluorometric assay. Blood 1990; 76: 18531859.
  • 33
    Dacie JV, Lewis SM. Paroxysmal nocturnal haemoglobinuria: Clinical manifestations, haematology, and nature of the disease. Ser Haematol 1972; 5: 323.
  • 34
    Galili N, Ravandi F, Palermo G, Bubis J, Illingworth A, Castro-Malaspina H, Raza A. Prevalence of paroxysmal nocutrnal hemoglobinuria (PNH) cells in patients with myelodysplastic syndromes (MDS), aplastic anemia (AA) or other bone marrow failure (BMF) synderomes: Interim results from the EXPLORE trial. J Clin Oncol 2009; 27: 15s.
  • 35
    Ariel O, Kukulansky T, Raz N, Hollander N. Distinct membrane localization and kinase association of the two isoforms of CD58. Cell Signal 2004; 16: 667673.
  • 36
    Navenot JM, Bernard D, Harousseau JL, Muller JY, Blanchard D Expression of glycosyl-phosphatidylinositol-linked glycoproteins in blood cells from paroxysmal nocturnal haemoglobinuria patients: A flow cytometry study using CD55. CD58 and CD59 monoclonal antibodies. Leuk Lymphoma 1996; 21: 143151.
  • 37
    Sutherland DR, Kuek N, Azcona-Olivera J, Anderson T, Acton E, Barth D, Keeney M. Use of a FLAER-based WBC assay in the primary screening of PNH clones. Am J Clin Pathol 2009; 132: 564572.
  • 38
    Reid ME, Mallinson G, Sim RB, Poole J, Pausch V, Merry AH, Liew YW, Tanner MJ. Biochemical studies on red blood cells from a patient with the Inab phenotype (decay-accelerating factor deficiency). Blood 1991; 78: 32913297.
  • 39
    Yamashina M, Ueda E, Kinoshita T, Takami T, Ojima A, Ono H, Tanaka H, Kondo N, Orii T, Okada N. Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1990; 323: 11841189.
  • 40
    Kinoshita T, Medof ME, Silber R, Nussenzweig V. Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria. J Exp Med 1985; 162: 7592.
  • 41
    Wang L, Wells DA, Deeg HJ, Loken MR. Flow cytometric detection of nonneoplastic antigenic polymorphisms of donor origin after allogeneic marrow transplant: A report of two cases. Am J Clin Pathol 2004; 122: 135140.
  • 42
    Olteanu H, Karandikar NJ, McKenna RW, Xu Y. Differential usefulness of various markers in the flow cytometric detection of paroxysmal nocturnal hemoglobinuria in blood and bone marrow. Am J Clin Pathol 2006; 126: 781788.
  • 43
    Movalia MK, Illingworth A. Identification and clinical significance of type II granulocytes among patients with paroxysmal nocturnal hemoglobinuria (PNH) identified using multiparameter high-sensitivity flow cytometry. Blood 2009; 114: 3015.
  • 44
    Gross HJ, Verwer B, Houck D, Recktenwald D. Detection of rare cells at a frequency of one per million by flow cytometry. Cytometry 1993; 14: 519526.
  • 45
    Gross HJ, Verwer B, Houck D, Hoffman RA, Recktenwald D. Model study detecting breast cancer cells in peripheral blood mononuclear cells at frequencies as low as 10(-7). Proc Natl Acad Sci USA 1995; 92: 537541.
  • 46
    Lewis SM, Dacie JV. The aplastic anaemia—Paroxysmal nocturnal haemoglobinuria syndrome. Br J Haematol 1967; 13: 236251.
  • 47
    Schubert J, Vogt HG, Zielinska-Skowronek M, Freund M, Kaltwasser JP, Hoelzer D, Schmidt RE. Development of the glycosylphosphatitylinositol-anchoring defect characteristic for paroxysmal nocturnal hemoglobinuria in patients with aplastic anemia. Blood 1994; 83: 23232328.
  • 48
    Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H. Antithymocyte globulin with or without cyclosporin A: 11-Year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 2003; 101: 12361242.
  • 49
    Tichelli A, Gratwohl A, Nissen C, Speck B Late clonal complications in severe aplastic anemia. Leuk Lymphoma 1994; 12: 167175.
  • 50
    Ishiyama K, Chuhjo T, Wang H, Yachie A, Omine M, Nakao S. Polyclonal hematopoiesis maintained in patients with bone marrow failure harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells. Blood 2003; 102: 12111216.
  • 51
    Dunn DE, Tanawattanacharoen P, Boccuni P, Nagakura S, Green SW, Kirby MR, Kumar MS, Rosenfeld S, Young NS. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med 1999; 131: 401408.
  • 52
    Sugimori C, Mochizuki K, Qi Z, Sugimori N, Ishiyama K, Kondo Y, Yamazaki H, Takami A, Okumura H, Nakao S. Origin and fate of blood cells deficient in glycosylphosphatidylinositol-anchored protein among patients with bone marrow failure. Br J Haematol 2009; 147: 102112.
  • 53
    Sugimori C, Chuhjo T, Feng X, Yamazaki H, Takami A, Teramura M, Mizoguchi H, Omine M, Nakao S. Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood 2006; 107: 13081314.
  • 54
    Yoshida N, Yagasaki H, Takahashi Y, Yamamoto T, Liang J, Wang Y, Tanaka M, Hama A, Nishio N, Kobayashi R, Hotta N, Asami K, Kikuta A, Fukushima T, Hirano N, Kojima S. Clinical impact of HLA-DR15, a minor population of paroxysmal nocturnal haemoglobinuria-type cells, and an aplastic anaemia-associated autoantibody in children with acquired aplastic anaemia. Br J Haematol 2008; 142: 427435.
  • 55
    Scheinberg P, Wu CO, Nunez O, Young NS. Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol 2009; 144: 206216.
  • 56
    Araten DJ, Nafa K, Pakdeesuwan K, Luzzatto L: Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc Natl Acad Sci USA 1999; 96: 52095214.
  • 57
    Hu R, Mukhina GL, Piantadosi S, Barber JP, Jones RJ, Brodsky RA. PIG-A mutations in normal hematopoiesis. Blood 2005; 105: 38483854.
  • 58
    Ware RE, Pickens CV, DeCastro CM, Howard TA. Circulating PIG-A mutant T lymphocytes in healthy adults and patients with bone marrow failure syndromes. Exp Hematol 2001; 29: 14031409.
  • 59
    Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. Blood 2009; 113: 65226527.
  • 60
    Traulsen A, Pacheco JM, Dingli D. On the origin of multiple mutant clones in paroxysmal nocturnal hemoglobinuria. Stem Cells 2007; 25: 30813084.
  • 61
    Brubaker LH, Essig LJ, Mengel CE. Neutrophil life span in paroxysmal nocturnal hemoglobinuria. Blood 1977; 50: 657662.
  • 62
    Richards SJ, Hill A, Hillmen P. Recent advances in the diagnosis, monitoring, and management of patients with paroxysmal nocturnal hemoglobinuria. Cytometry B 2007; 72B: 291298.
  • 63
    Saunthararajah Y, Nakamura R, Nam JM, Robyn J, Loberiza F, Maciejewski JP, Simonis T, Molldrem J, Young NS, Barrett AJ. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002; 100: 15701574.